Sequana Medical NV
XBRU:SEQUA
Net Margin
Sequana Medical NV
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| BE |
|
Sequana Medical NV
XBRU:SEQUA
|
50.3m EUR |
-42 126%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.4B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
192.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
154.6B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.9B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.4B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.1B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.1B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.5B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
281.2B CNY |
31%
|
Sequana Medical NV
Glance View
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sequana Medical NV's most recent financial statements, the company has Net Margin of -42 126.4%.
You don't have any saved screeners yet